share_log

康寧傑瑞製藥-B：內幕消息公告 - 有關KN046治療晚期PDAC的III期臨床試驗的最新進展

ALPHAMAB-B: INSIDE INFORMATION ANNOUNCEMENT - UPDATES IN RELATION TO A PHASE III CLINICAL TRIAL OF KN046FOR THE TREATMENT OF ADVANCED PDAC

HKEX ·  May 28 10:08
Summary by Moomoo AI
康寧傑瑞生物製藥（ALPHAMAB ONCOLOGY）於2024年5月28日宣布，其KN046-303 III期臨床試驗已達到預設的死亡事件數，但總生存期（OS）結果未達到預設的統計學終點。KN046-303試驗是一項針對未接受系統性治療的不可切除局部晚期或轉移性胰腺導管腺癌（PDAC）患者的多中心、隨機、雙盲、安慰劑對照試驗，旨在評估KN046聯合白蛋白紫杉醇及吉西他濱對比安慰劑聯合白蛋白紫杉醇及吉西他濱的療效及安全性。公司董事會提醒投資者，根據香港聯合交易所有限公司證券上市規則第18A.05條的警示聲明，無法確保KN046能成功開發或上市，股東及潛在投資者應審慎行事。
康寧傑瑞生物製藥（ALPHAMAB ONCOLOGY）於2024年5月28日宣布，其KN046-303 III期臨床試驗已達到預設的死亡事件數，但總生存期（OS）結果未達到預設的統計學終點。KN046-303試驗是一項針對未接受系統性治療的不可切除局部晚期或轉移性胰腺導管腺癌（PDAC）患者的多中心、隨機、雙盲、安慰劑對照試驗，旨在評估KN046聯合白蛋白紫杉醇及吉西他濱對比安慰劑聯合白蛋白紫杉醇及吉西他濱的療效及安全性。公司董事會提醒投資者，根據香港聯合交易所有限公司證券上市規則第18A.05條的警示聲明，無法確保KN046能成功開發或上市，股東及潛在投資者應審慎行事。
CORNING JERRY BIOPHARMACEUTICALS (ALPHAMAB ONCOLOGY) ANNOUNCED ON MAY 28, 2024 THAT ITS PHASE III CLINICAL TRIAL KN046-303 HAD REACHED THE DEFAULT NUMBER OF DEATHS, BUT OVERALL SURVIVAL (OS) RESULTS DID NOT REACH THE DEFAULT STATISTICAL ENDPOINT. Trial KN046-303 is a multicenter, randomized, double-blind, placebo-controlled trial in patients with unresectable locally advanced or metastatic pancreatic cancer (PDAC) who have not received systemic therapy, designed to evaluate KN046 Combination Proteins and Guisetabain versus placebo Combination Protein Violet EFFICACY AND SAFETY OF SUGAROL AND GISITAMAM The Board of Directors reminds investors that the warning statement of Section 18A.05 of the Securities Listing Rules of Hong Kong Stock Exchange Limited cannot ensure that KN046 can be successfully developed or listed. Shareholders and potential investors should exercise caution.
CORNING JERRY BIOPHARMACEUTICALS (ALPHAMAB ONCOLOGY) ANNOUNCED ON MAY 28, 2024 THAT ITS PHASE III CLINICAL TRIAL KN046-303 HAD REACHED THE DEFAULT NUMBER OF DEATHS, BUT OVERALL SURVIVAL (OS) RESULTS DID NOT REACH THE DEFAULT STATISTICAL ENDPOINT. Trial KN046-303 is a multicenter, randomized, double-blind, placebo-controlled trial in patients with unresectable locally advanced or metastatic pancreatic cancer (PDAC) who have not received systemic therapy, designed to evaluate KN046 Combination Proteins and Guisetabain versus placebo Combination Protein Violet EFFICACY AND SAFETY OF SUGAROL AND GISITAMAM The Board of Directors reminds investors that the warning statement of Section 18A.05 of the Securities Listing Rules of Hong Kong Stock Exchange Limited cannot ensure that KN046 can be successfully developed or listed. Shareholders and potential investors should exercise caution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more